Nomad Power Solutions, Inc. (NMAD) vs Xilio Therapeutics, Inc. (XLO)

Nomad Power Solutions, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Nomad Power Solutions, Inc. and Xilio Therapeutics, Inc. are of similar size ($59.2M and $58.5M). Nomad Power Solutions, Inc. has the higher net margin (0.00% vs −34.1%) and the lower return on invested capital (−40.4% vs 0.00%). Across the 12 metrics below, Nomad Power Solutions, Inc. leads on 7 and Xilio Therapeutics, Inc. on 5.

Valuation

Metric NMAD XLO Biotechnology median
P/E n/m n/m 7.88
P/S n/m 2.74 11.47
P/B 1.93 2.43 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 0.75 10.73
Earnings yield (27.93%) (16.49%) (28.84%)
Free cash flow yield (11.31%) (34.93%) (23.03%)

Profitability

Metric NMAD XLO Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (48.94%) 0.00%
Net margin 0.00% (34.06%) 0.00%
Free cash flow margin 0.00% (95.59%) 0.00%
Return on equity (68.04%) (55.03%) (57.72%)
Return on assets (62.67%) (15.16%) (49.22%)
Return on invested capital (40.41%) 0.00% 0.00%

Growth

Metric NMAD XLO Biotechnology median
Revenue growth (TTM) — 327.25% 5.64%
EPS growth (last fiscal year) 20.75% 72.55% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NMAD XLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.87 4.25 4.73
Net debt to EBITDA 1.00 3.40 0.96

Dividend

Metric NMAD XLO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NMAD XLO Biotechnology median
Market cap 58.45m 59.22m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack